CRISPR Technology Market by Offering, Application, End User

List of Tables

[183 Pages Report] The CRISPR Technology Market size was estimated at USD 3.25 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 16.52% to reach USD 9.49 billion by 2030.

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a highly precise and efficient genome-editing tool derived from a bacterial defense mechanism, which allows for targeted manipulation of the DNA sequence within an organism's genome. This innovative biotechnology tool enables precise genome editing through RNA-guided Cas9 nucleases, facilitating targeted genetic modifications across healthcare, agriculture, and bioenergy industries. Increased funding for research activities, advancements in gene therapy, the growing prevalence of genetic disorders, and the need for more efficient crop production methods increase the use of CRISPR technology. However, ethical concerns surrounding gene editing, especially in human germline cells, and regulatory hurdles in different regions may impede the adoption or commercialization of CRISPR products. Nevertheless, creating new genetically modified crops (GMO) with enhanced nutritional value or resistance to pests and diseases and advancing drug discovery by screening large libraries of compounds against specific targets using CRISPR systems creates lucrative opportunities for the CRISPR technology market.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.25 billion
Estimated Year [2024]	USD 3.77 billion
Forecast Year [2030]	USD 9.49 billion
CAGR (%)	16.52%

Offering: Increasing use of CRISPR kits & reagents with the surging research activities and product improvements

The enzymes used in CRISPR technology are critical components for gene editing, with Cas9 being the most commonly utilized enzyme. These enzymes function as molecular scissors, enabling precise cutting and modification of DNA sequences. Guide RNAs have significance in directing the Cas enzymes to target specific genomic locations within a cell's DNA sequence. Researchers may require custom gRNAs designed for their particular targets or prefer pre-designed libraries that cover common gene targets in model organisms or cell lines. The CRISPR kits & reagent product portfolio comprises a range of products, including plasmids, Cas9 proteins, sgRNAs (single guide RNAs), expression vectors, homology-directed repair (HDR) templates, viral delivery systems such as adeno-associated viruses (AAV) or lentiviruses, electroporation-based transfection methods including nucleofection devices or lipofection reagents. Cell line engineering services involve modifying cells to introduce or enhance specific features using CRISPR technology, enabling researchers to study gene function and develop targeted therapies. This service is crucial for biopharmaceutical companies and academic institutions focused on drug discovery, gene therapy, and regenerative medicine. The design and construction of guide RNAs (gRNAs) and vector systems are essential in CRISPR-mediated gene editing experiments. Researchers rely on these services for generating knockout or knock-in models with high efficiency and specificity, which is particularly important in applications such as functional genomics, target validation studies, and disease modeling. CRISPR-based screening services are pivotal for identifying novel drug targets or uncovering critical genetic interactions within biological pathways.

Application: Proliferating use of CRISPR technology in the agricultural sector

In the agricultural sector, CRISPR technology provides solutions for crop improvement, pest and disease resistance, and increased yield. CRISPR technology has applications in biomedical research, such as gene therapy for genetic disorders, cancer immunotherapy, and infectious disease treatment. The industrial applications of CRISPR technology encompass microbial engineering, biofuels, biomaterials, and environmental bioremediation.

End-User: Potential application of CRISPR technology in biotechnology companies

Academic and government research institutes primarily focus on fundamental research and developing novel applications for CRISPR technology. Their need-based preference for CRISPR revolves around generating advanced knowledge and tools to understand the mechanism behind gene editing, targeting specific genes in the human genome, and finding potential therapeutic solutions for various genetic disorders. Biotechnology companies utilizing CRISPR technology focus on applied research with commercial applications such as agriculture optimization, industrial bioprocessing enhancement, or direct-to-consumer genetic modification products. Pharmaceutical companies involve therapeutic applications of CRISPR technology for drug discovery and development, specifically targeting genetic diseases, cancers, or lifestyle disorders such as obesity.

Regional Insights

In America, the CRISPR technology market represents significant growth due to extensive research and development activities, substantial investments by both public and private sectors, and advances in bioinformatics. In addition, robust and steadily growing sectors such as agriculture, biotechnology, drug discovery, and therapeutics increased demand for CRISPR technology. The APAC region boasts increasing biopharmaceutical industries investing heavily in gene-editing technologies for agricultural advancements and disease treatment applications. Additionally, factors such as government support for genomics research and strategic collaborations with international organizations have accelerated market growth in this region. Europe has experienced considerable growth due to its well-established pharmaceutical infrastructure and funding from various organizations for genome editing research projects. Moreover, the Middle-East and Africa sub-segments focus on therapeutic applications of CRISPR for diseases such as sickle cell anemia and beta-thalassemia.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the CRISPR Technology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CRISPR Technology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CRISPR Technology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Applied StemCell, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., ERS Genomics Limited, Function Oncology, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Scribe Therapeutics, Sherlock Biosciences, Inc., Synthego Corporation, Takara Holdings Inc., Thermo Fisher Scientific Inc., ToolGen, Inc., TriLink BioTechnologies by Maravai Intermediate Holdings, LLC, Twist Bioscience Corporation, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the CRISPR Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering
- Product
  - Enzymes
  - Guide RNA
  - Kits & Reagents

Services
- Cell Line Engineering
- gRNA Design & Vector Construction
- Screening Services

Application
- Agricultural
- Biomedical
- Industrial

End User
- Academics & Government Research Institutes
- Biotechnology Companies
  - Agricultural Companies
  - Pharmaceutical Companies
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Georgia
    - Illinois
    - Kentucky
    - Michigan
    - Mississippi
    - New Jersey
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the CRISPR Technology Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CRISPR Technology Market?

3. What are the technology trends and regulatory frameworks in the CRISPR Technology Market?

4. What is the market share of the leading vendors in the CRISPR Technology Market?

5. Which modes and strategic moves are suitable for entering the CRISPR Technology Market?

Product Code: MRR-B1685377A648

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing need for new vaccines and treatments for genetic diseases
  - 5.1.1.2. Increasing private and public investments in biotechnological and pharmaceutical sectors
- 5.1.2. Restraints
  - 5.1.2.1. High cost and complexities involved in the government regulations
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements and improvements in CRISPR technology
  - 5.1.3.2. Potential use of CRISPR technology in the agriculture sector
- 5.1.4. Challenges
  - 5.1.4.1. Technical challenges and ethical concerns associated with CRISPR technology
5.2. Market Segmentation Analysis
- 5.2.1. Offering: Increasing use of CRISPR kits & reagents with the surging research activities and product improvements
- 5.2.2. Application: Proliferating use of CRISPR technology in the agricultural sector
- 5.2.3. End-User: Potential application of CRISPR technology in biotechnology companies
5.3. Market Trend Analysis
- 5.3.1. Increasing research and development by key players and growing application of CRISPR technology in agriculture in the Americas
- 5.3.2. Ongoing research and strategic collaborations for higher agricultural productivity using CRISPR technologies coupled with adoption of CRISPR in point-of-care testing in the APAC region
- 5.3.3. Increasing approvals for the usage of CRISPR technology for disease management coupled with growing research activities in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
5.8. Client Customization
- 5.8.1. CRISPR becoming a viable solution for bioenergy production
- 5.8.2. Expanding patent landscape for CRISPR technology

6. CRISPR Technology Market, by Offering

6.1. Introduction
6.2. Product
6.3. Services

7. CRISPR Technology Market, by Application

7.1. Introduction
7.2. Agricultural
7.3. Biomedical
7.4. Industrial

8. CRISPR Technology Market, by End User

8.1. Introduction
8.2. Academics & Government Research Institutes
8.3. Biotechnology Companies

9. Americas CRISPR Technology Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific CRISPR Technology Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa CRISPR Technology Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. RoslinCT Manufacture CRISPR-Based Therapy
- 12.3.2. First Human CRISPR Drug Moves Forward
- 12.3.3. ERS Genomics Limited ('ERS') Completes Licensing Agreement With Syngene International
- 12.3.4. Revvity's (RVTY) New Launch to Widen Access to Editing Technology
- 12.3.5. Pencil Biosciences Raises GBP 5.6 Million to Advance Gene Editing for Rare Diseases
- 12.3.6. Integrated DNA Technologies and Aldevron Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers
- 12.3.7. Bedoukian Research Inc. Partners with Inscripta to Sustainably Develop and Manufacture Naturally Produced Ingredients
- 12.3.8. Scribe Announces Collaboration to Accelerate In Vivo CRISPR-Based Genetic Medicines
- 12.3.9. Vertex Teases Launch Plans for First Crispr Gene Editing Therapy Ahead of FDA Decision
- 12.3.10. Sherlock Biosciences to Acquire Sense Biodetection
- 12.3.11. Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio